Back to School: How biopharma can reboot drug development. Access exclusive analysis here

PxRadia: Ceramide selectivity

PxRadia mAbs target ceramide build-up to treat GI radiation syndrome

PxRadia Inc. is developing a mAb that directly targets ceramide molecules in the cell membrane, blocking their ability to induce apoptosis in tissues subjected to stressors such as radiation. But the mAb doesn't impair normal ceramide synthesis or metabolism, meaning it may be safer than other ceramide-targeting compounds in development.

The company is pursuing gastrointestinal acute radiation syndrome (GI ARS), but also sees applications for preventing stem cell death in cytolytic T cell-mediated autoimmune diseases like

Read the full 759 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers